Table 15:
Summary of Results for Review of GeneSight to Support Psychotropic Medication Selection Among Patients With Mood Disorders
| Outcome | Measure | Results | GRADE |
|---|---|---|---|
| Patient Outcomes | |||
| Suicide | Mortality | None reported | NA |
| Remission of depression symptoms | Depression below a predefined threshold: HAMD-17 <8, QIDS-C16 <5 or PHQ-9 <5 | No significant difference between groupsa | Very low |
| Response to depression therapy | At least 50% reduction in depression scores based on HAMD-17, QIDS-C16, or PHQ-9 | Favoured guided therapy | Low to very low |
| Measures of depression | % reduction in score (improvement in depression) HAMD-17 | Favoured guided therapy | Very low |
| QIDS-C16 | Favoured guided therapy | Very low | |
| PHQ-9 | Favoured guided therapy | Very low | |
| Quality of life | Validated measures of quality of life | None reported | NA |
| Secondary Outcomes | |||
| Impact on therapeutic decisions | Changes to medications | Inconsistent measurement outcome resulted in either no significant difference or observed difference in favour of guided therapy | Very low |
| Satisfaction | Patient satisfaction | Favoured guided therapy | Very low |
| Clinician satisfaction | Favoured guided therapy | Low | |
Abbreviations: GRADE, Grading of Recommendations Assessment, Development, and Evaluation; HAMD-17, 17-item Hamilton Rating Scale for Depression; NA, not applicable; NS, not significant; PHQ-9, 9-item Patient Health Questionnaire; QIDS-C16, 16-item Quick Inventory of Depressive Symptomatology, clinician rating.
a
No significant difference when using the HAMD-17 or PHQ-9 measures; a significant result was observed with the QIDS-C16 in favour of guided care.